This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
by Zacks Equity Research
Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.
Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care
by Debanjana Dey
HIMS expands its weight loss platform with a bundled Wegovy program and tech-driven obesity care solutions.
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
by Ahan Chakraborty
NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.
Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?
by Kinjel Shah
PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.
Will CVS Health's Formulary Move Boost Its Weight Management Program?
by Moumi Mondal
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.
HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?
by Ethan Feller
Hims & Hers stock crashes 30% on Monday after news of Novo Nordisk ending their partnership. Is HIMS now a compelling stock to buy?
LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?
by Kinjel Shah
LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
by Ahan Chakraborty
LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
by Ahan Chakraborty
Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
by Ekta Bagri
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
by Zacks Equity Research
VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the preceding trading day.
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
by Ahan Chakraborty
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
HTO or CWST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HTO vs. CWST: Which Stock Is the Better Value Option?
PFE or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
VNT vs. DUOL: Which Stock Is the Better Value Option?
by Zacks Equity Research
VNT vs. DUOL: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Eli Lilly, Home Depot, SAP and Natural Resource Partners
by Zacks Equity Research
Eli Lilly, Home Depot, SAP and NRP highlight key themes in pharma, retail, cloud growth???and energy sector challenges.
Top Analyst Reports for Eli Lilly, Home Depot & SAP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and SAP SE.
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
by Kinjel Shah
LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?
NVO Stock up on Plans to Advance Obesity Candidate Amycretin
by Zacks Equity Research
Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.
NVO Stock Gains After Parvus Asset Management Builds Stake
by Zacks Equity Research
Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline buzz.
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
by Kinjel Shah
LLY banks on soaring Mounjaro and Zepbound sales to defend its obesity edge amid intensifying competition.